{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+for+correlative+studies&page=24", "query": { "intervention": "Peripheral blood for correlative studies", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 618, "total_pages": 62, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+for+correlative+studies&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+for+correlative+studies&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T20:49:00.202Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01168219", "title": "Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Adult Acute Megakaryoblastic Leukemia", "Adult Acute Monoblastic Leukemia", "Adult Acute Monocytic Leukemia", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With Maturation", "Adult Acute Myeloid Leukemia With Minimal Differentiation", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL", "Adult Acute Myeloid Leukemia Without Maturation", "Adult Acute Myelomonocytic Leukemia", "Adult Erythroleukemia", "Adult Pure Erythroid Leukemia", "Alkylating Agent-Related Acute Myeloid Leukemia", "de Novo Myelodysplastic Syndrome", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 68, "start_date": "2010-07-15", "completion_date": "2020-02-01", "has_results": true, "last_update_posted_date": "2022-08-04", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 17, "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 12 more", "locations": [ { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01168219" }, { "nct_id": "NCT03271372", "title": "Adjuvant Avelumab in Merkel Cell Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage III Merkel Cell Carcinoma AJCC v8", "Stage IIIB Merkel Cell Carcinoma AJCC v8", "Stage IIIA Merkel Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Peripheral Blood Collection", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2017-12-19", "completion_date": "2029-02-18", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 9, "location_summary": "Orange, California • Aurora, Colorado • Tampa, Florida + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271372" }, { "nct_id": "NCT02259218", "title": "Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adult Brain Tumor", "Lung Cancer", "Radiation Toxicity" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 273, "start_date": "2012-10-04", "completion_date": "2025-09-17", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02259218" }, { "nct_id": "NCT03373760", "title": "Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 67, "start_date": "2017-11-30", "completion_date": "2022-03-29", "has_results": true, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 1021, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 643 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03373760" }, { "nct_id": "NCT00904241", "title": "Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ganglioneuroblastoma", "Localized Resectable Neuroblastoma", "Localized Unresectable Neuroblastoma", "Regional Neuroblastoma", "Stage 4 Neuroblastoma", "Stage 4S Neuroblastoma" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 10000, "start_date": "2000-11-06", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 223, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 157 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00904241" }, { "nct_id": "NCT01275677", "title": "Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2/Neu Positive", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3270, "start_date": "2011-02-08", "completion_date": "2025-06-02", "has_results": true, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 1259, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01275677" }, { "nct_id": "NCT01093586", "title": "Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Erythroleukemia (M6a)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Adult Pure Erythroid Leukemia (M6b)", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Burkitt Lymphoma", "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)", "Childhood Acute Monoblastic Leukemia (M5a)", "Childhood Acute Monocytic Leukemia (M5b)", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Secondary Myelofibrosis", "Splenic Marginal Zone Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage II Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "double-unit umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "cytogenetic analysis", "type": "OTHER" }, { "name": "bone marrow aspiration", "type": "PROCEDURE" }, { "name": "fluorescence in situ hybridization", "type": "OTHER" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "12 Years to 64 Years" }, "enrollment_count": 14, "start_date": "2007-09", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2019-01-23", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01093586" }, { "nct_id": "NCT03373305", "title": "Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD30-Positive Neoplastic Cells Present", "Folliculotropic Mycosis Fungoides", "Recurrent Mycosis Fungoides", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-03", "completion_date": "2019-04-26", "has_results": false, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03373305" }, { "nct_id": "NCT01953640", "title": "Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 92, "start_date": "2013-05-30", "completion_date": "2023-04-03", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01953640" }, { "nct_id": "NCT03522584", "title": "Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Hypofractionated Image-Guided Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "RADIATION", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-05-17", "completion_date": "2022-01-19", "has_results": true, "last_update_posted_date": "2023-06-12", "last_synced_at": "2026-10-15T20:49:00.202Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03522584" } ] }